FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schenkein David P (Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 12/03/2015 4. If Amendment, Date of Original Filed (Month/Day/Year)							e L	X X . Indivine)	call application of the control of t	icable) or r (give title) hief Execu Joint/Group filed by One n	10% Owner		pplicable
				saction Day/Year)	ion 2A. Deemed Execution Date,			3. Transacti Code (Ins 8) Code	on str. V	4. Securities Acquired Disposed Of (D) (Instr. and 5) Amount (A) or (D) Fosed of, or Benefici		or Pri	or 4	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Forr (D) o	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	le of ative Conversion Date Or Exercise Price of Derivative Security Conversion Date Conversion D		4. Transac Code (I	ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tive ties ed sed 3, 4	C. Date Exer Expiration I (Month/Day/	rcisa Date /Year	ble and r)	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amount or Numl of Title Shari		8. Price of Derivati Security (Instr. 5		Beneficiall	Ownership Form: Direct (D) or Indirect (I) (Instr.	Ownership Form: Direct (D) or Indirect (I) (Instr.	Beneficial Ownership	
Stock option (right to buy)	\$9.05	12/03/2015		A		68,181	(0)	(1)	Г	/29/2023	Common	68,18	1	\$0.00	935,501		D	

Explanation of Responses:

1. This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to an additional 50% upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of the option as to 68,181 shares. The second performance milestone has not yet been met.

Remarks:

/s/ Glenn Goddard, as
Attorney-in-Fact for David 12/07/2015
Schenkein

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.